Figure 1 | Scientific Reports

Figure 1

From: Cost-effectiveness of CYP2C19 genotyping to guide antiplatelet therapy for acute minor stroke and high-risk transient ischemic attack

Figure 1

One-way sensitivity analyses on incremental cost-effectiveness ratio (ICER) gained by genetic testing. Numbers listed in parentheses indicate the range of the variable. Dark-shaded bars represent the lower bound of the variable range. Light-shaded bars represent the upper bound. Solid vertical lines represent the ICER of the clopidogrel-aspirin regimen at the base-case scenario (CNY 13,552.74/QALY). QALYs, quality adjusted life years.

Back to article page